持続皮下インスリン注入治療機器(CSITD)の世界市場2019-2023

◆英語タイトル:Global Continuous Subcutaneous Insulin Therapy Devices (CSITD) Market 2019-2023
◆商品コード:IRTNTR30346
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年12月3日
◆ページ数:111
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、持続皮下インスリン注入治療機器(CSITD)の世界市場について調査・分析し、市場概要、市場環境、持続皮下インスリン注入治療機器(CSITD)市場規模、製品別(繋留、パッチ)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・持続皮下インスリン注入治療機器(CSITD)の世界市場概要
・持続皮下インスリン注入治療機器(CSITD)の世界市場環境
・持続皮下インスリン注入治療機器(CSITD)の世界市場動向
・持続皮下インスリン注入治療機器(CSITD)の世界市場規模
・持続皮下インスリン注入治療機器(CSITD)の世界市場:業界構造分析
・持続皮下インスリン注入治療機器(CSITD)の世界市場:製品別(繋留、パッチ)
・持続皮下インスリン注入治療機器(CSITD)の世界市場:地域別市場規模・分析
・持続皮下インスリン注入治療機器(CSITD)の北米市場規模・予測
・持続皮下インスリン注入治療機器(CSITD)のヨーロッパ・中東・アフリカ市場規模・予測
・持続皮下インスリン注入治療機器(CSITD)のアジア太平洋市場規模・予測
・持続皮下インスリン注入治療機器(CSITD)の主要国分析
・持続皮下インスリン注入治療機器(CSITD)の世界市場:意思決定フレームワーク
・持続皮下インスリン注入治療機器(CSITD)の世界市場:成長要因、課題
・持続皮下インスリン注入治療機器(CSITD)の世界市場:競争環境
・持続皮下インスリン注入治療機器(CSITD)の世界市場:関連企業情報(ベンダー分析)

主な分析対象企業は、Cellnovo、F. Hoffmann-La Roche、Insulet、Medtronic、Tandem Diabetes Careなどです。
【レポートの概要】

About this market
The rising partnerships to gain prominence in the market. Vendors are entering into strategic alliances and partnerships for integration of available and emerging technologies into their products. Such partnerships will help the market to grow. Technavio’s analysts have predicted that the continuous subcutaneous insulin therapy devices market will register a CAGR of more than 9% by 2023.
Market Overview
Rise in awareness about diabetes
The rise in prevalence of diabetes has resulted in increasing awareness efforts by various organizations globally. Programs such as the Diabetes Activities Under State Public Health Actions increase the participation of people.
Rise in product recalls
The growth of the market is hindered by product recalls. Product recalls affect the sales of a company negatively, which results in a decline in it market share. Also, they affect the brand image of vendors, thereby reducing profit margins.
For the detailed list of factors that will drive and challenge the growth of the continuous subcutaneous insulin therapy devices market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be concentrated and with the presence of several companies including Medtronic and Tandem Diabetes Care the competitive environment is quite intense. Factors such as the rising partnerships and the rise in awareness about diabetes, will provide considerable growth opportunities to continuous subcutaneous insulin therapy devices manufactures. Cellnovo, F. Hoffmann-La Roche, Insulet, Medtronic, and Tandem Diabetes Care are some of the major companies covered in this report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Tethered – Market size and forecast 2018-2023
• Patch – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 10: MARKET TRENDS
• Technological advances
• Increase in grants for product development
• Rise in strategic partnerships
PART 11: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 12: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Cellnovo
• F. Hoffmann-La Roche
• Insulet
• Medtronic
• Tandem Diabetes Care
PART 13: APPENDIX
• Research methodology
• List of abbreviations


Exhibit 01: Years in consideration
Exhibit 02: Global medical devices market
Exhibit 03: Segments of global medical devices market
Exhibit 04: Market characteristics
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Product – Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Tethered – Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Tethered – Year-over-year growth 2019-2023 (%)
Exhibit 21: Patch – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Patch – Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 29: Top 3 countries in Americas
Exhibit 30: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in EMEA
Exhibit 33: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in APAC
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Decision framework
Exhibit 39: Patients diagnosed with diabetes in US 1995-2015
Exhibit 40: Rates of children aged under 14 years with type 1 diabetes per 1,000 population 2015
Exhibit 41: Product launches
Approval year
Regulatory body
Description
Exhibit 42: Product recalls in global CSITD market
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: Cellnovo – Vendor overview
Exhibit 50: Cellnovo – Organizational developments
Exhibit 51: Cellnovo – Geographic focus
Exhibit 52: Cellnovo – Key offerings
Exhibit 53: F. Hoffmann-La Roche – Vendor overview
Exhibit 54: F. Hoffmann-La Roche – Business segments
Exhibit 55: F. Hoffmann-La Roche – Organizational developments
Exhibit 56: F. Hoffmann-La Roche – Geographic focus
Exhibit 57: F. Hoffmann-La Roche – Segment focus
Exhibit 58: F. Hoffmann-La Roche – Key offerings
Exhibit 59: Insulet – Vendor overview
Exhibit 60: Insulet – Organizational developments
Exhibit 61: Insulet – Geographic focus
Exhibit 62: Insulet – Key offerings
Exhibit 63: Medtronic – Vendor overview
Exhibit 64: Medtronic – Business segments
Exhibit 65: Medtronic – Organizational developments
Exhibit 66: Medtronic – Geographic focus
Exhibit 67: Medtronic – Segment focus
Exhibit 68: Medtronic – Key offerings
Exhibit 69: Tandem Diabetes Care – Vendor overview
Exhibit 70: Tandem Diabetes Care – Organizational developments
Exhibit 71: Tandem Diabetes Care – Key offerings
Exhibit 72: Validation techniques employed for market sizing
Exhibit 73: List of abbreviations




【掲載企業】

Cellnovo、F. Hoffmann-La Roche、Insulet、Medtronic、Tandem Diabetes Care

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[持続皮下インスリン注入治療機器(CSITD)の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆